Why Did Beta Drugs (NSE: BETA) Shares Slide Nearly 9% After Q4 Results?
Why Did Beta Drugs (NSE: BETA) Shares Slide Nearly 9% After Q4 Results?
No news articles found at the moment.
No matches found for your search.
Loading market ticker...
Ashish Agarwal brings over 15 years of experience in technical analysis and automated signal–driven market strategies, specialising in equity and commodities markets across the UK, Australia, and India. He holds an MBA in Finance and a degree in Data Science, combining market expertise with a strong data-driven approach. His core strengths include price action analysis, trend identification, momentum indicators, and systematic auto-signal frameworks. Known for his clear communication and structured analytical style, Ashish delivers insightful, technically focused market commentary. He joined the Kalkine team in April 2024, contributing high-quality research and informed global market perspectives.
Why Did Beta Drugs (NSE: BETA) Shares Slide Nearly 9% After Q4 Results?
MIRC Electronics (NSE: MIRCELECTR) Stock in Focus After Sharp Pullback From Multi-Month Highs
HUDCO (NSE: HUDCO) Stock Falls Over 7% as Investors React to Earnings and Valuation Concerns
P N Gadgil Jewellers (NSE: PNGJL) Share Price Tumbles Following Q4 Earnings Update
Mold-Tek Technologies (NSE: MOLDTECH) Shares in Focus After Sharp Post-Earnings Decline
Why Did Saregama India Limited (NSE: SAREGAMA) Shares Surge After Strong Q4 Profit Growth and Music Content Expansion?